Recent News

• 06.05.2025 - Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
• 05.20.2025 - H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
• 05.14.2025 - Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
• 05.13.2025 - First Quarter 2025 Financial Results Earnings Call
• 05.13.2025 - Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.12.2025 - RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
• 05.01.2025 - Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
• 04.22.2025 - Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
• 04.21.2025 - Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Recent Filings

• 05.13.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.01.2025 - 8-K Current report
• 04.29.2025 - ARS Annual Report to Security Holders
• 04.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2025 - DEF 14A Other definitive proxy statements
• 04.24.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities